2026– date –
-
HHS Unveils Strategy to Accelerate US Drug Discovery, Stemming Clinical Trial Shift to China
BioPharma Dive USA Overview The U.S. Department of Health and Human Services (HHS) has launched a comprehensive initiative to accelerate early-stage drug research domestically, directly countering the recent trend of clinical trials migr... -
Major Setback: Pfizer’s Seagen-Acquired ADC Fails Phase 3 in Advanced Lung Cancer
BioPharma Dive USA Overview Pfizer's antibody-drug conjugate (ADC), sigvotatug vedotin, acquired through its Seagen acquisition, failed to meet its primary endpoint of improved overall survival (OS) in a Phase 3 clinical trial for patien... -
Vertex AI-Designed Candidates Hit Phase 1/2 Trials, Accelerating AI-Driven Drug Discovery
Vertex AI Search (PharmaJournalist) USA Overview Multiple AI-designed drug candidates, developed using Vertex AI Search, have advanced to Phase 1 and 2 clinical trials, firmly establishing AI as a pivotal force in pharmaceutical R&D.... -
Breaking the Blood-Brain Barrier: Next-Gen Strategies Unveil Neurological Drug Delivery Innovation
Pharmaceutical Conferences 2026 International会議 Overview A recent conference on June 22, 2026, showcased groundbreaking drug delivery strategies designed to circumvent the formidable blood-brain barrier (BBB). These innovations, includ... -
HHS Launches Cross-Agency Initiative to Restore US Clinical Trial Leadership, Leveraging AI/ML for Enhanced Safety & Efficiency
HHS.gov USA Overview The U.S. Department of Health and Human Services (HHS) has launched a landmark cross-agency initiative to restore the nation's leadership in clinical trials. This effort integrates artificial intelligence (AI) and ma... -
ClinicalTrials.gov Completes Modern Platform Migration, Dramatically Elevating Clinical Trial Data Access and Transparency
ClinicalTrials.gov USA Overview ClinicalTrials.gov has successfully transitioned to a modernized Protocol Registration and Results System (PRS) platform, significantly enhancing the accessibility and transparency of clinical trial inform... -
FDA Greenlights 24 Drugs in May 2026, Featuring AbbVie’s Decnupaz ADC and Shionogi’s Xocova COVID-19 Oral
BioWorld USA Overview The U.S. FDA approved 24 drugs in May 2026, marking the highest number of approvals in a single month this year, with eight being novel molecular entities (NMEs). This surge includes AbbVie's CD123-targeting antibod... -
FDA Greenlights Breakthrough TNBC Therapies, First-in-Class Hypertriglyceridemia Drug, and New Breast Cancer Maintenance Regimen
FDA USA Overview On June 24, 2026, the U.S. FDA announced pivotal approvals across several cancer and metabolic disease indications, introducing significant new therapeutic options. These include a breakthrough for triple-negative breast... -
Oral GLP-1 Aleniglipron Achieves 12% Weight Loss in Phase II, Poised to Transform Obesity Treatment
Health and Me / Northwestern University USA Overview The novel oral GLP-1 receptor agonist, aleniglipron, demonstrated an impressive average 12% body weight reduction over 36 weeks in obese or overweight patients during a Phase II clinic... -
Murata Manufacturing Enhances All-Solid-State Microbattery Energy Density and Cycle Life for Wearables
EE Times Japan Japan Overview Murata Manufacturing has updated its progress in all-solid-state microbattery technology, targeting small electronic devices and wearables. The company reported improvements in energy density and cycle life ...
